Clinical trial
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
NCT01438489 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT01438489 |
|---|---|
| Title | A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus |
| Official title | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Biological, Other |
| Interventions | Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo |
| Enrollment | 626 |
| Start date | Jan 1, 2012 |
| Primary completion | Apr 1, 2015 |
| Completion | Apr 1, 2015 |
| First posted | Sep 22, 2011 |
| Last update posted | Oct 7, 2016 |
| Countries | Brazil, Bulgaria, Colombia, Czechia, Hungary, India, Mexico, Peru, Poland, Romania, South Korea, Taiwan and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: